ESPR

Esperion Therapeutics (ESPR)

Esperion Therapeutics Inc

から:

Regulatory News

Text Search:

次の項目別のソート:

Non-Regulatory News

Showing the most relevant articles for your search:NASDAQ:ESPR

1 2 3 4 5 6 7 8 9 10 次へ >>

日付	受信時刻	ニュースソース	見出し	コード	企業名
2024/05/14	21 : 00	GlobeNewswire Inc.	Esperion Receives Five Year Patent Extension for Bempedoic Acid, Contained in NEXLETOL® and NEXLIZET®	NASDAQ:ESPR	Esperion Therapeutics Inc
2024/05/11	05 : 00	GlobeNewswire Inc.	Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)	NASDAQ:ESPR	Esperion Therapeutics Inc
2024/05/09	05 : 31	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:ESPR	Esperion Therapeutics Inc
2024/05/07	21 : 50	Edgar (US Regulatory)	Form 10-Q - Quarterly report [Sections 13 or 15(d)]	NASDAQ:ESPR	Esperion Therapeutics Inc
2024/05/07	20 : 29	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:ESPR	Esperion Therapeutics Inc
2024/05/07	19 : 00	GlobeNewswire Inc.	Esperion Reports First Quarter 2024 Financial Results	NASDAQ:ESPR	Esperion Therapeutics Inc
2024/04/29	21 : 00	GlobeNewswire Inc.	Esperion to Participate in Upcoming May Investor Conferences	NASDAQ:ESPR	Esperion Therapeutics Inc
2024/04/23	21 : 00	GlobeNewswire Inc.	Esperion to Report First Quarter 2024 Financial Results on May 7	NASDAQ:ESPR	Esperion Therapeutics Inc
2024/04/08	03 : 45	GlobeNewswire Inc.	Esperion Presents Important New Data from CLEAR Outcomes at ACC.24 Highlighting Value of NEXLETOL® (bempedoic acid) Tablets in Diverse Populations Including Women, Hispanics/Latinx and Patients with Obesity	NASDAQ:ESPR	Esperion Therapeutics Inc
2024/04/01	21 : 00	GlobeNewswire Inc.	Esperion to Ring Nasdaq Opening Bell Today, April 1, 2024	NASDAQ:ESPR	Esperion Therapeutics Inc
2024/03/26	21 : 00	GlobeNewswire Inc.	Esperion to Participate in 23rd Annual Needham Virtual Healthcare Conference	NASDAQ:ESPR	Esperion Therapeutics Inc
2024/03/26	05 : 00	GlobeNewswire Inc.	Esperion Announces Data from CLEAR Outcomes Sub-Groups as Poster Presentations, Moderated Session & Industry Expert Theatre to be Presented at ACC.24	NASDAQ:ESPR	Esperion Therapeutics Inc
2024/03/23	07 : 26	Business Wire	U.S. FDA Approves Broad New Labels for Esperion’s NEXLETOL® and NEXLIZET® to Prevent Heart Attacks and Cardiovascular Procedures in Both Primary and Secondary Prevention Patients, Regardless of Statin Use	NASDAQ:ESPR	Esperion Therapeutics Inc
2024/03/23	04 : 10	GlobeNewswire Inc.	U.S. FDA Approves Broad New Labels for NEXLETOL® and NEXLIZET® to Prevent Heart Attacks and Cardiovascular Procedures in Both Primary and Secondary Prevention Patients, Regardless of Statin Use	NASDAQ:ESPR	Esperion Therapeutics Inc
2024/03/23	00 : 04	GlobeNewswire Inc.	CHMP Issues Positive Opinions For Both Bempedoic Acid And The Bempedoic Acid / Ezetimibe Fixed-Dose Combination Tablet As Treatments For Hypercholesterolemia And Significantly Reducing Cardiovascular Events	NASDAQ:ESPR	Esperion Therapeutics Inc
2024/02/27	23 : 19	Edgar (US Regulatory)	Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]	NASDAQ:ESPR	Esperion Therapeutics Inc
2024/02/27	21 : 23	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:ESPR	Esperion Therapeutics Inc
2024/02/27	20 : 00	GlobeNewswire Inc.	Esperion Reports Fourth Quarter and Full Year 2023 Financial Results	NASDAQ:ESPR	Esperion Therapeutics Inc
2024/02/17	06 : 30	GlobeNewswire Inc.	Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)	NASDAQ:ESPR	Esperion Therapeutics Inc
2024/02/15	04 : 14	Edgar (US Regulatory)	Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]	NASDAQ:ESPR	Esperion Therapeutics Inc
2024/02/15	00 : 50	Edgar (US Regulatory)	Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]	NASDAQ:ESPR	Esperion Therapeutics Inc
2024/02/14	22 : 42	Edgar (US Regulatory)	Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]	NASDAQ:ESPR	Esperion Therapeutics Inc
2024/02/14	20 : 11	Edgar (US Regulatory)	Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]	NASDAQ:ESPR	Esperion Therapeutics Inc
2024/02/13	22 : 00	GlobeNewswire Inc.	Esperion to Report Fourth Quarter and Full Year 2023 Financial Results on February 27	NASDAQ:ESPR	Esperion Therapeutics Inc
2024/02/02	04 : 00	GlobeNewswire Inc.	RFK, Esperion Therapeutics Announce 2024 Promotional Schedule	NASDAQ:ESPR	Esperion Therapeutics Inc
2024/01/24	06 : 00	GlobeNewswire Inc.	Esperion Announces Closing of Public Offering of Common Stock and Exercise in Full of Underwriters’ Option to Purchase Additional Shares	NASDAQ:ESPR	Esperion Therapeutics Inc
2024/01/22	20 : 10	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:ESPR	Esperion Therapeutics Inc
2024/01/22	20 : 04	Edgar (US Regulatory)	Form 424B5 - Prospectus [Rule 424(b)(5)]	NASDAQ:ESPR	Esperion Therapeutics Inc
2024/01/19	11 : 15	GlobeNewswire Inc.	Esperion Announces Pricing of $85.1 Million Public Offering of Common Stock	NASDAQ:ESPR	Esperion Therapeutics Inc
2024/01/19	06 : 03	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:ESPR	Esperion Therapeutics Inc